These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 38571961)

  • 61. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
    Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ
    Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Human liver cancer organoids: Biological applications, current challenges, and prospects in hepatoma therapy.
    Chen L; Wei X; Gu D; Xu Y; Zhou H
    Cancer Lett; 2023 Feb; 555():216048. PubMed ID: 36603689
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Personalized Proteome Profiles of Healthy and Tumor Human Colon Organoids Reveal Both Individual Diversity and Basic Features of Colorectal Cancer.
    Cristobal A; van den Toorn HWP; van de Wetering M; Clevers H; Heck AJR; Mohammed S
    Cell Rep; 2017 Jan; 18(1):263-274. PubMed ID: 28052255
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Organoid technology in cancer precision medicine.
    Xia X; Li F; He J; Aji R; Gao D
    Cancer Lett; 2019 Aug; 457():20-27. PubMed ID: 31078736
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hepatobiliary Organoids and Their Applications for Studies of Liver Health and Disease: Are We There Yet?
    Shiota J; Samuelson LC; Razumilava N
    Hepatology; 2021 Oct; 74(4):2251-2263. PubMed ID: 33638203
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tumor organoids: applications in cancer modeling and potentials in precision medicine.
    Xu H; Jiao D; Liu A; Wu K
    J Hematol Oncol; 2022 May; 15(1):58. PubMed ID: 35551634
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
    Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Modeling neoplastic disease with spheroids and organoids.
    Zanoni M; Cortesi M; Zamagni A; Arienti C; Pignatta S; Tesei A
    J Hematol Oncol; 2020 Jul; 13(1):97. PubMed ID: 32677979
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Organoid Culture Development for Skeletal Systems.
    Qing J; Guo Q; Lv L; Zhang X; Liu Y; Heng BC; Li Z; Zhang P; Zhou Y
    Tissue Eng Part B Rev; 2023 Oct; 29(5):545-557. PubMed ID: 37183418
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Breast cancer organoids derived from patients: A platform for tailored drug screening.
    Tzeng YT; Hsiao JH; Tseng LM; Hou MF; Li CJ
    Biochem Pharmacol; 2023 Nov; 217():115803. PubMed ID: 37709150
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and future perspectives (Review).
    Cao J; Chan WC; Chow MSS
    Int J Oncol; 2022 May; 60(5):. PubMed ID: 35322860
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phenotypic heterogeneity of 2D organoid reflects clinical tumor characteristics.
    Fujino S; Ito A; Ohue M; Yasui M; Mizushima T; Doki Y; Mori M; Miyoshi N
    Biochem Biophys Res Commun; 2019 May; 513(2):332-339. PubMed ID: 30955861
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Exploration of organoid in breast cancer related research].
    Zheng X; Li J; Sheng J; Zhuo Q; Du Q; Xu Y
    Sheng Wu Gong Cheng Xue Bao; 2021 Feb; 37(2):395-403. PubMed ID: 33645143
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tumor Organoids as a Research Tool: How to Exploit Them.
    Booij TH; Cattaneo CM; Hirt CK
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359838
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Establishment of patient-derived cancer organoids for drug-screening applications.
    Driehuis E; Kretzschmar K; Clevers H
    Nat Protoc; 2020 Oct; 15(10):3380-3409. PubMed ID: 32929210
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Biomaterials for intestinal organoid technology and personalized disease modeling.
    Hirota A; AlMusawi S; Nateri AS; Ordóñez-Morán P; Imajo M
    Acta Biomater; 2021 Sep; 132():272-287. PubMed ID: 34023456
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Accuracy of Using a Patient-Derived Tumor Organoid Culture Model to Predict the Response to Chemotherapy Regimens In Stage IV Colorectal Cancer: A Blinded Study.
    Wang T; Pan W; Zheng H; Zheng H; Wang Z; Li JJ; Deng C; Yan J
    Dis Colon Rectum; 2021 Jul; 64(7):833-850. PubMed ID: 33709991
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Organoids: The current status and biomedical applications.
    Yang S; Hu H; Kung H; Zou R; Dai Y; Hu Y; Wang T; Lv T; Yu J; Li F
    MedComm (2020); 2023 Jun; 4(3):e274. PubMed ID: 37215622
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tumor Organoid as a Drug Screening Platform for Cancer Research.
    Mahbubi R; Yousefi N; Hamidieh AA; Gholizadeh F; Sisakht MM
    Curr Stem Cell Res Ther; 2023 Oct; ():. PubMed ID: 37855289
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Gastrointestinal cancer organoids-applications in basic and translational cancer research.
    Seidlitz T; Stange DE
    Exp Mol Med; 2021 Oct; 53(10):1459-1470. PubMed ID: 34663939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.